APICES
Apices is a full-service Contract Research Organization (CRO) founded in 2009, dedicated to providing high-quality, tailor-made services in clinical research. With a focus on innovation, sustainability, and excellence, it covers a broad spectrum of therapeutic areas including oncology, hematology, rare diseases, and more. The company emphasizes compliance with regulations and has achieved certifications such as ISO 9001:2015, ISO 26000:2010, EcoVadis, and SBTi. Apices aims to improve patient outcomes and medical advancements through its comprehensive services and solutions.
Industries
Nr. of Employees
medium (51-250)
Products
White paper: Recognition of the work of a CRO
White paper describing the contributions of a contract research organisation across the clinical research process and its value to sponsors.
White paper: Recognition of the work of a CRO
White paper describing the contributions of a contract research organisation across the clinical research process and its value to sponsors.
Services
End-to-end outsourced services covering study design, start-up, monitoring, data management, biostatistics, pharmacovigilance, quality assurance and medical writing.
Services from project definition to site selection and CRF design to prepare studies for execution.
Tailored data-management services including validated EDC deployment, CRF configuration and data-integrity processes to support regulatory compliance.
Provision of hosted project platforms, investigator/client portals and access to hosted data-capture systems for study stakeholders.
Safety support from individual tasks to full outsourcing of sponsor pharmacovigilance responsibilities, including safety reporting processes.
Biostatistical planning and analysis with statistical programming support for clinical and observational studies, including pooled RWD analyses.
End-to-end outsourced services covering study design, start-up, monitoring, data management, biostatistics, pharmacovigilance, quality assurance and medical writing.
Services from project definition to site selection and CRF design to prepare studies for execution.
Tailored data-management services including validated EDC deployment, CRF configuration and data-integrity processes to support regulatory compliance.
Provision of hosted project platforms, investigator/client portals and access to hosted data-capture systems for study stakeholders.
Safety support from individual tasks to full outsourcing of sponsor pharmacovigilance responsibilities, including safety reporting processes.
Biostatistical planning and analysis with statistical programming support for clinical and observational studies, including pooled RWD analyses.
Expertise Areas
- Clinical trial management (Phase I–IV)
- Study start-up and regulatory submissions
- Monitoring strategies including risk-based and centralized monitoring
- Clinical data management and validated EDC implementation
Key Technologies
- Validated electronic data capture (EDC) platforms
- Clinical trial management systems (CTMS) and project portals
- Statistical programming and analysis workflows
- Risk-based monitoring and centralized monitoring methodologies
News & Updates
The ASCO 2025 congress in Chicago, Illinois, united the global oncology community to discuss the latest breakthroughs in cancer research. APICES, with 16 years of experience in oncology clinical trials, participated actively.
APICES received acknowledgment for its collaboration in the NSCLC retrospective ORIGEN study, published in ESMO 2023 congress, involving start-up, project management, monitoring, biostatistics, and medical writing activities.
APICES was acknowledged for its ongoing collaboration in the international Phase III BEATcc trial in cervical cancer, highlighted during an oral presentation at ESMO Gynecological Cancers Congress 2025.
APICES emphasizes sustainability and environmental management as core responsibilities, contributing to healthcare innovation and patient outcomes.
APICES is an author and received acknowledgment in the NALOPOOL RWD study on opioid-induced constipation in cancer patients, published in Cancers. APICES contributed to statistical analysis.
APICES received acknowledgment for its collaboration in the ORIGEN NSCLC retrospective study, published in ESMO 2023 congress, involving start-up, project management, monitoring, biostatistics, and medical activities.
The ASCO 2025 congress in Chicago, Illinois, united the global oncology community to discuss the latest breakthroughs in cancer research. APICES, with 16 years of experience in oncology clinical trials, participated actively.
APICES received acknowledgment for its collaboration in the NSCLC retrospective ORIGEN study, published in ESMO 2023 congress, involving start-up, project management, monitoring, biostatistics, and medical writing activities.
APICES was acknowledged for its ongoing collaboration in the international Phase III BEATcc trial in cervical cancer, highlighted during an oral presentation at ESMO Gynecological Cancers Congress 2025.
APICES emphasizes sustainability and environmental management as core responsibilities, contributing to healthcare innovation and patient outcomes.
APICES is an author and received acknowledgment in the NALOPOOL RWD study on opioid-induced constipation in cancer patients, published in Cancers. APICES contributed to statistical analysis.
APICES received acknowledgment for its collaboration in the ORIGEN NSCLC retrospective study, published in ESMO 2023 congress, involving start-up, project management, monitoring, biostatistics, and medical activities.